瑞科生物-B(02179)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02179 瑞科生物-B

交易中 05-07 15:18:43

8.960

-0.240

-2.61%

最高9.300	最低8.790	成交量2.90万
今开9.300	昨收9.200	日振幅5.54%
总市值43.27亿	流通市值28.33亿	总股本4.83亿
成交额26.35万	换手率0.01%	流通股本3.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02179","market":"HK","secType":"STK","nameCN":"瑞科生物-B","latestPrice":8.96,"timestamp":1715065846497,"preClose":9.2,"halted":0,"volume":29000,"delay":0,"floatShares":316138689,"shares":482963000,"eps":-1.2877952,"marketStatus":"交易中","marketStatusCode":2,"change":-0.24,"latestTime":"05-07 15:18:43","open":9.3,"high":9.3,"low":8.79,"amount":263510,"amplitude":0.055435,"askPrice":9.15,"askSize":3500,"bidPrice":8.73,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-1.2877952319203163,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1715069400000},"adr":0,"listingDate":1648656000000,"adjPreClose":9.2,"openAndCloseTimeList":[[1715045400000,1715054400000],[1715058000000,1715068800000]],"volumeRatio":11.826496,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02179/wiki","defaultTab":"wiki","newsList":[{"id":"2427079777","title":"瑞科生物-B(02179)提名刘勇为第二届董事会执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2427079777","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2427079777?lang=zh_cn&edition=full","pubTime":"2024-04-15 19:32","pubTimestamp":1713180732,"startTime":"0","endTime":"0","summary":"第二届董事会董事任期三年，自公司股东大会审议通过相关议案之日起生效，任期届满可以连选连任。此外，鉴于公司第一届监事会任期将于2024年5月到期，为保持监事会正常运作，根据《中华人民共和国公司法》和公司章程的规定，监事会于2024年4月15日召开的监事会会议上拟选举钱然婷、王飞舟为第二届监事会非职工代表监事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1102751.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422986715","title":"瑞科生物与荣盛生物就新型佐剂疫苗项目签署战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2422986715","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2422986715?lang=zh_cn&edition=full","pubTime":"2024-03-27 11:01","pubTimestamp":1711508460,"startTime":"0","endTime":"0","summary":"泰州2024年3月27日 /美通社/ --近日，江苏瑞科生物技术股份有限公司与上海荣盛生物药业股份有限公司在上海成功举办新型佐剂疫苗研发项目签约暨项目启动会议。根据该协议条款，双方将联合开展新型佐剂疫苗的开发，瑞科生物将提供基于新型佐剂技术平台自主研发的新型佐剂，荣盛生物将提供自主设计的病毒抗原。我们期待与荣盛生物的战略合作早日结出硕果，也相信双方的合作将进一步推动人用疫苗的创新发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4372075_ZH72075_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422559611","title":"瑞科生物－Ｂ(02179)股价上升6.25%，现价港币$8.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2422559611","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422559611?lang=zh_cn&edition=full","pubTime":"2024-03-25 13:03","pubTimestamp":1711342980,"startTime":"0","endTime":"0","summary":"[上升股]瑞科生物－Ｂ(02179) 股价在下午01:03比前收市价上升6.25%，现股价为港币$8.5。至目前为止，今日最高价为$8.5，而最低价为$8.5。总成交量为500股，总成交金额为港币$4250。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2403251526/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2421377853","title":"瑞科生物发布2023全年业绩报告及最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2421377853","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2421377853?lang=zh_cn&edition=full","pubTime":"2024-03-21 00:18","pubTimestamp":1710951480,"startTime":"0","endTime":"0","summary":"江苏省泰州2024年3月21日 /美通社/ -- 3月20日，创新型疫苗公司瑞科生物发布2023全年业绩报告及最新进展。瑞科生物始终秉持\"创制一流疫苗，守护人类健康\"的愿景使命，以公司战略为导向，在研管线及业务运营方面达到以下里程碑及进展。此前，本公司REC610在菲律宾开展以葛兰素史克Shingrix为阳性对照的FIH临床试验。十年磨剑，厚积薄发，瑞科生物即将进入产品商业化的爆发期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4366646_ZH66646_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420714659","title":"《公司业绩》瑞科生物-B(02179.HK)全年亏损收窄至5.72亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420714659","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2420714659?lang=zh_cn&edition=full","pubTime":"2024-03-20 18:31","pubTimestamp":1710930660,"startTime":"0","endTime":"0","summary":"瑞科生物-B(02179.HK) 公布截至去年12月底止全年业绩，其他收入及收益 1.01亿元，按年跌32.1%。亏损收窄至5.72亿元，上年同期蚀7.23亿元；每股亏损1.19元。不派息。(ad/u)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2023/08/25中期业绩无派息2023/03/20末期业绩无派息 2022/08/25中期业绩无派息 2022/04/27末期业绩无派息 AASTOCKS新闻","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220328112941280_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220328112941280_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1335108/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2420711189","title":"瑞科生物-B(02179)发布年度业绩 股东应占亏损5.72亿元 同比收窄20.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420711189","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2420711189?lang=zh_cn&edition=full","pubTime":"2024-03-20 18:28","pubTimestamp":1710930514,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞科生物-B(02179)发布截至2023年12月31日止年度的全年业绩，该集团期内取得其他收入及收益1.01亿元(人民币，下同)，同比减少32.05%;股东应占亏损5.72亿元，同比收窄20.86%;每股基本亏损1.19元。公告称，其他收入及收益减少是由于因外币交易产生的汇兑收益减少9760万元;利息收入增加2160万元;及政府补助增加2510万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1089180.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417084486","title":"瑞科生物-B(02179.HK)拟3月20日举行董事会会议考虑及通过年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2417084486","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2417084486?lang=zh_cn&edition=full","pubTime":"2024-03-08 16:51","pubTimestamp":1709887880,"startTime":"0","endTime":"0","summary":"格隆汇3月8日丨瑞科生物-B(02179.HK)公告，董事会会议将于2024年3月20日(星期三)举行，藉以(其中包括)审议及批准公司及其附属公司截至2023年12月31日止年度全年业绩及其发布，并考虑派发末期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240308165305876489c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240308165305876489c7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2409417839","title":"瑞科生物－Ｂ(02179)股价下跌5.263%，现价港币$8.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2409417839","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2409417839?lang=zh_cn&edition=full","pubTime":"2024-02-06 13:05","pubTimestamp":1707195900,"startTime":"0","endTime":"0","summary":"[下跌股]瑞科生物－Ｂ(02179) 股价在下午01:05比前收市价下跌5.263%，现股价为港币$8.1。至目前为止，今日最高价为$8.35，而最低价为$8.1。总成交量为3.3万股，总成交金额为港币$27.525万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2402062478/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2407870206","title":"瑞科生物新佐剂重组带状疱疹疫苗中国I期临床研究完成首批受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2407870206","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2407870206?lang=zh_cn&edition=full","pubTime":"2024-01-30 13:36","pubTimestamp":1706592971,"startTime":"0","endTime":"0","summary":"瑞科生物(2179.HK)宣布其自主研发的新佐剂重组带状疱疹疫苗REC610中国I期临床试验已完成首批受试者入组。该研究采用随机、双盲、平行对照设计，在云南省普洱市共招募180例40岁及以上健康受试者，以评价REC610的安全性、耐受性和免疫原性。根据公司此前消息，该产品已完成在菲律宾开展的与GSK Shingrix头对头比对临床研究，结果显示REC610在细胞免疫和体液免疫方面均与Shingrix相当。2023年10月，中国CDE同意豁免REC610的中国II期临床，批准公司直接在中国开展I期和III期研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401301336158159f798&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401301336158159f798&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2405746631","title":"华泰证券：受益于老龄化、低渗透率、国产营销 中国带状疱疹疫苗市场有望提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2405746631","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2405746631?lang=zh_cn&edition=full","pubTime":"2024-01-24 14:44","pubTimestamp":1706078648,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华泰证券发布研究报告称，中国带状疱疹疫苗市场进入大幅增长阶段，2023 年市场规模约30亿，预计2024~2026 年市场增速约180%、80%、40%：1)中老年人接种池庞大且数量持续增长;2)该行估算中国2023 年50 岁以上城镇人口接种率0.5%、累计渗透率0.8%，距离美国2021年年度接种率4.6%与累计渗透率18.5%存在较大差距;3)供给与销售出现大幅好转，百克于2023 年上市、GSK 于2024 年交付智飞生物，2026 年起重组蛋白国产化将启动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1060409.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2405194011","title":"瑞科生物与SPIMACO就重组九价HPV疫苗在中东及北非15国市场达成授权与战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2405194011","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2405194011?lang=zh_cn&edition=full","pubTime":"2024-01-23 14:47","pubTimestamp":1705992440,"startTime":"0","endTime":"0","summary":"瑞科生物日前已与沙特阿拉伯制药公司SPIMACO就重组九价HPV疫苗REC603签署框架协议并达成授权与战略合作。根据协议，瑞科生物独家授权SPIMACO在含沙特阿拉伯等15个中东及北非国家对重组九价HPV疫苗REC603进行开发、注册与商业化。SPIMACO公司是沙特阿拉伯最大的上市药企之一，深度参与中东及北非区域的政府招标及私人自费市场，产品广泛覆盖中东北非国家。瑞科生物与SPIMACO公司的合作，将有助于开拓中东北非及更多市场，加速创新疫苗商业化进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012314490281d9e61f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012314490281d9e61f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2400838528","title":"瑞科生物(02179.HK)：能否成为带状疱疹疫苗领域的潜力黑马？","url":"https://stock-news.laohu8.com/highlight/detail?id=2400838528","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2400838528?lang=zh_cn&edition=full","pubTime":"2024-01-02 13:35","pubTimestamp":1704173702,"startTime":"0","endTime":"0","summary":"瑞科生物REC610在菲律宾开展以Shingrix为阳性对照的FIH 临床试验期中分析数据显示，在40岁及以上健康受试者中，接种两剂REC610总体安全、耐受性良好。未报告SAE、AESI、因AE提前退出。","market":"us","thumbnail":"https://img3.gelonghui.com/88dbe-d6dba55c-69f7-41fc-8980-cdace33e6e65.jpg?guru_height=853&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/88dbe-d6dba55c-69f7-41fc-8980-cdace33e6e65.jpg?guru_height=853&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/679783","is_publish_highlight":false,"gpt_icon":0},{"id":"2395704971","title":"东曜药业-B盘中异动 临近收盘股价大涨7.41%报2.030港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2395704971","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2395704971?lang=zh_cn&edition=full","pubTime":"2023-12-29 16:05","pubTimestamp":1703837134,"startTime":"0","endTime":"0","summary":"2023年12月29日临近收盘16时05分，东曜药业-B股票出现波动，股价大幅拉升7.41%。截至发稿，该股报2.030港元/股，成交量9600股，换手率0.00%，振幅6.35%。资金方面，该股资金流入1.8088万港元，流出0港元。东曜药业-B股票所在的生物技术行业中，整体跌幅为0.07%。东曜药业-B公司简介：东曜药业股份有限公司是一家主要从事开发及商业化肿瘤药物及疗法的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122916053487e627ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122916053487e627ab&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2395774677","title":"新佐剂重组带状疱疹疫苗REC610在菲律宾临床试验期中分析中取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2395774677","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2395774677?lang=zh_cn&edition=full","pubTime":"2023-12-29 12:28","pubTimestamp":1703824080,"startTime":"0","endTime":"0","summary":"泰州2023年12月29日 /美通社/ -- 瑞科生物欣然宣布，本公司自主研发的新佐剂重组带状疱疹疫苗REC610，已于近期在菲律宾首次人体临床试验期中分析中取得积极结果。此前，本公司REC610在菲律宾开展以葛兰素史克Shingrix为阳性对照的FIH临床试验。同时，REC610在老年及成年人群均可诱导较好的体液免疫和细胞免疫应答。根据全球已上市的带状疱疹疫苗研究数据，相比减毒活疫苗，新佐剂重组带状疱疹疫苗能提供更强的细胞免疫和保护效力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4301918_ZH01918_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2395772160","title":"瑞科生物-B(02179)：新佐剂重组带状疱疹疫苗REC610在菲律宾临床试验期中分析取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2395772160","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2395772160?lang=zh_cn&edition=full","pubTime":"2023-12-29 12:08","pubTimestamp":1703822897,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞科生物-B 发布公告，公司自主研发的新佐剂重组带状疱疹疫苗REC610，已于近期在菲律宾首次人体临床试验期中分析取得积极结果。此前，公司REC610在菲律宾开展以葛兰素史克Shingrix为阳性对照的FIH 临床试验。该研究期中分析数据显示，在40岁及以上健康受试者中，接种两剂REC610总体安全、耐受性良好。同时，REC610在老年及成年人群均可诱导较好的体液免疫和细胞免疫应答。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1047345.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2393769129","title":"格隆汇·全球投资嘉年华·2024之“金格奖”——年度卓越公司榜单全部揭晓！","url":"https://stock-news.laohu8.com/highlight/detail?id=2393769129","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2393769129?lang=zh_cn&edition=full","pubTime":"2023-12-21 13:01","pubTimestamp":1703134908,"startTime":"0","endTime":"0","summary":"看看哪些公司上榜了！","market":"hk","thumbnail":"https://img7.gelonghui.com/column/5.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/5.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/676234","is_publish_highlight":false,"gpt_icon":0},{"id":"2382258094","title":"智通港股沽空统计|11月9日","url":"https://stock-news.laohu8.com/highlight/detail?id=2382258094","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2382258094?lang=zh_cn&edition=full","pubTime":"2023-11-09 08:20","pubTimestamp":1699489214,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示，华润啤酒-R、长城汽车-R、小米集团-WR上一交易日沽空比率位于前三位，分别为100.00%、89.84%、83.21%。中国平安、小米集团-W、腾讯控股的沽空金额位居前三，分别为6.07 亿元、5.50 亿元、4.47 亿元。浙江沪杭甬、长飞光纤光缆、舜宇光学科技的偏离值位居前三，分别为39.44%、30.03%、27.21%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1021894.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0397},{"period":"3month","weight":0.0455},{"period":"6month","weight":-0.1727},{"period":"1year","weight":-0.3611},{"period":"ytd","weight":-0.1529}],"compareEarnings":[{"period":"1week","weight":0.0468},{"period":"1month","weight":0.1109},{"period":"3month","weight":0.1513},{"period":"6month","weight":0.0575},{"period":"1year","weight":-0.0734},{"period":"ytd","weight":0.0898}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏瑞科生物技术股份有限公司是一家从事疫苗研发的中国公司。该公司拥有一系列临床和临床前阶段的疫苗，人乳头瘤病毒（HPV）疫苗管线包括重组HPV九价候选疫苗REC603，重组HPV二价候选疫苗REC601及REC602，重组HPV四价疫苗REC604a以及重组HPV九价疫苗REC604b。该公司还参与新冠病毒疫苗的研发。该公司主要在国内市场销售其产品。","exchange":"SEHK","name":"瑞科生物-B","nameEN":"RECBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞科生物-B(02179)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞科生物-B(02179)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞科生物-B,02179,瑞科生物-B股票,瑞科生物-B股票老虎,瑞科生物-B股票老虎国际,瑞科生物-B行情,瑞科生物-B股票行情,瑞科生物-B股价,瑞科生物-B股市,瑞科生物-B股票价格,瑞科生物-B股票交易,瑞科生物-B股票购买,瑞科生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞科生物-B(02179)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞科生物-B(02179)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}